L. Skordos

Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates

R. Pendleton, G. Rodgers, Michelle Wheeler, 2005, American journal of hematology.

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

S. Haeberlein, P. Chiao, A. Sandrock, 2017, The journal of prevention of Alzheimer's disease.

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

S. Haeberlein, I. Nestorov, A. Sandrock, 2020, Alzheimer's & Dementia.

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

F. Barkhof, P. Aisen, C. Mummery, 2022, The Journal of Prevention of Alzheimer's Disease.

Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004)

S. Haeberlein, R. Nitsch, C. Hock, 2018 .

Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001)

S. Haeberlein, S. Salloway, P. Aisen, 2019 .